Literature DB >> 10818189

Heparin therapy and reversal of protein-losing enteropathy in a case with congenital heart disease.

I Bendayán1, J Casaldaliga, F Castelló, L Miró.   

Abstract

We describe a patient with tricuspid hypoplasia who developed a protein-losing enteropathy. Having failed to respond to medical and surgical treatments, a heparin regimen was started with immediate decrease in enteric protein loss.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10818189     DOI： 10.1007/s002460010055

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


  9 in total

1.  Heparin in Congenital Chylothorax and Chylous Ascites.

Authors:  María Soriano-Ramos; Elena Orellana-Felis; María Teresa Moral-Pumarega; María López-Maestro; Concepción de Alba-Romero; Alberto Galindo-Izquierdo; Carmen Rosa Pallás-Alonso
Journal:  Indian J Pediatr       Date:  2019-04-22       Impact factor: 1.967

2.  Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions.

Authors:  Candice K Silversides; Omid Salehian; Erwin Oechslin; Markus Schwerzmann; Isabelle Vonder Muhll; Paul Khairy; Eric Horlick; Mike Landzberg; Folkert Meijboom; Carole Warnes; Judith Therrien
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

3.  Fenestration of the Fontan circuit as treatment for plastic bronchitis.

Authors:  J Wilson; J Russell; W Williams; L Benson
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

4.  Plastic bronchitis in children with Fontan palliation: analogue to protein losing enteropathy?

Authors:  B Stiller; F Riedel; K Paul; F K H van Landeghem
Journal:  Pediatr Cardiol       Date:  2002 Jan-Feb       Impact factor: 1.655

5.  Protein-Losing Enteropathy and Gastropathy.

Authors:  Brian R. Landzberg; Mark B. Pochapin
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

Review 6.  Medical management of the failing Fontan.

Authors:  N S Ghanayem; S Berger; J S Tweddell
Journal:  Pediatr Cardiol       Date:  2007 Nov-Dec       Impact factor: 1.655

7.  Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.

Authors:  Martin Floer; Martin Götte; Martin K Wild; Jan Heidemann; Ezeddin Salem Gassar; Wolfram Domschke; Ludwig Kiesel; Andreas Luegering; Torsten Kucharzik
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

8.  Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.

Authors:  Lars Bode; Camilla Salvestrini; Pyong Woo Park; Jin-Ping Li; Jeffrey D Esko; Yu Yamaguchi; Simon Murch; Hudson H Freeze
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

9.  Protein-losing enteropathy in ulcerative colitis.

Authors:  Ryan Ungaro; Mark W Babyatsky; Hongfa Zhu; Jeffrey S Freed
Journal:  Case Rep Gastroenterol       Date:  2012-04-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.